Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up on Strong Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s share price gapped up prior to trading on Wednesday following a stronger than expected earnings report. The stock had previously closed at $25.81, but opened at $28.48. Ultragenyx Pharmaceutical shares last traded at $25.43, with a volume of 406,705 shares.

The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.32. The firm had revenue of $214.00 million for the quarter, compared to analysts’ expectations of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The business’s revenue was up 28.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.17) earnings per share.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reported a second-quarter loss of $0.90 per share, beating the consensus estimate for a $1.22 loss and improving from a $1.17 loss in the year-ago quarter. Revenue rose 28.5% year over year to $214 million, exceeding analysts’ $183.08 million estimate. Ultragenyx Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: Product performance was led by Crysvita revenue of $156 million and Dojolvi revenue of $27 million, supporting the company’s revenue growth. Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Management reaffirmed 2026 revenue guidance of $730 million to $760 million and expects combined research and development and selling, general and administrative expenses to be flat to slightly lower than in 2025. Ultragenyx remains on track for profitability in 2027. Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Investors have multiple second-half catalysts to watch, including two FDA PDUFA decisions and pivotal Phase 3 Aspire data for GTX-102 in Angelman syndrome. Ultragenyx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Guggenheim lowered its price target from $43 to $35, although it maintained a Buy rating. The revised target still implies meaningful potential upside but signals more cautious valuation expectations. Guggenheim Price Target Update

Analyst Upgrades and Downgrades

RARE has been the subject of a number of research reports. Wedbush lowered their target price on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Barclays decreased their price target on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. Wall Street Zen raised shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Morgan Stanley upped their target price on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, April 16th. Finally, Royal Bank Of Canada increased their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.94.

Insider Activity

In other news, CFO Howard Horn sold 4,653 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $23.77, for a total value of $110,601.81. Following the sale, the chief financial officer owned 105,689 shares of the company’s stock, valued at approximately $2,512,227.53. This represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total transaction of $46,753.38. Following the transaction, the executive vice president directly owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 14,292 shares of company stock valued at $351,644 over the last ninety days. 5.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Oppenheimer Asset Management Inc. bought a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $221,000. Handelsbanken Fonder AB lifted its stake in shares of Ultragenyx Pharmaceutical by 17.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 39,523 shares of the biopharmaceutical company’s stock worth $1,320,000 after acquiring an additional 6,000 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 149.5% during the 2nd quarter. GAMMA Investing LLC now owns 1,919 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 1,150 shares during the last quarter. Harbor Investment Advisory LLC purchased a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at $52,000. Finally, Versant Capital Management Inc boosted its holdings in Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,001 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 1.0%

The company has a 50-day simple moving average of $27.77 and a 200 day simple moving average of $24.76. The company has a market cap of $2.52 billion, a P/E ratio of -4.18 and a beta of 0.35.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.